226 related articles for article (PubMed ID: 20078608)
1. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).
Sinclair SR; Kane SA; Van der Schueren BJ; Xiao A; Willson KJ; Boyle J; de Lepeleire I; Xu Y; Hickey L; Denney WS; Li CC; Palcza J; Vanmolkot FH; Depré M; Van Hecken A; Murphy MG; Ho TW; de Hoon JN
Br J Clin Pharmacol; 2010 Jan; 69(1):15-22. PubMed ID: 20078608
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.
Li CC; Vermeersch S; Denney WS; Kennedy WP; Palcza J; Gipson A; Han TH; Blanchard R; De Lepeleire I; Depré M; Murphy MG; Van Dyck K; de Hoon JN
Br J Clin Pharmacol; 2015 May; 79(5):831-7. PubMed ID: 25377933
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model.
Van der Schueren BJ; Rogiers A; Vanmolkot FH; Van Hecken A; Depré M; Kane SA; De Lepeleire I; Sinclair SR; de Hoon JN
J Pharmacol Exp Ther; 2008 Apr; 325(1):248-55. PubMed ID: 18216286
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.
Van der Schueren BJ; de Hoon JN; Vanmolkot FH; Van Hecken A; Depre M; Kane SA; De Lepeleire I; Sinclair SR
Br J Clin Pharmacol; 2007 Nov; 64(5):580-90. PubMed ID: 17578484
[TBL] [Abstract][Full Text] [Related]
6. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men.
Van der Schueren BJ; Blanchard R; Murphy MG; Palcza J; De Lepeleire I; Van Hecken A; Depré M; de Hoon JN
Br J Clin Pharmacol; 2011 May; 71(5):708-17. PubMed ID: 21480950
[TBL] [Abstract][Full Text] [Related]
7. The influence of migraine and female hormones on capsaicin-induced dermal blood flow.
Ibrahimi K; Vermeersch S; Frederiks P; Geldhof V; Draulans C; Buntinx L; Lesaffre E; MaassenVanDenBrink A; de Hoon J
Cephalalgia; 2017 Oct; 37(12):1164-1172. PubMed ID: 27687880
[TBL] [Abstract][Full Text] [Related]
8. Lack of hemodynamic interaction between CGRP-receptor antagonist telcagepant (MK-0974) and sumatriptan: results from a randomized study in patients with migraine.
Depré M; Macleod C; Palcza J; Behm M; de Lepeleire I; Han T; Panebianco D; Smith W; Blanchard R; Chodakewitz J; Murphy M; de Hoon J
Cephalalgia; 2013 Dec; 33(16):1292-301. PubMed ID: 23798725
[TBL] [Abstract][Full Text] [Related]
9. Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model.
Vermeersch S; Benschop RJ; Van Hecken A; Monteith D; Wroblewski VJ; Grayzel D; de Hoon J; Collins EC
J Pharmacol Exp Ther; 2015 Sep; 354(3):350-7. PubMed ID: 26116630
[TBL] [Abstract][Full Text] [Related]
10. Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca
Erdling A; Sheykhzade M; Edvinsson L
J Headache Pain; 2017 Dec; 18(1):61. PubMed ID: 28560541
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries.
Chan KY; Edvinsson L; Eftekhari S; Kimblad PO; Kane SA; Lynch J; Hargreaves RJ; de Vries R; Garrelds IM; van den Bogaerdt AJ; Danser AH; Maassenvandenbrink A
J Pharmacol Exp Ther; 2010 Sep; 334(3):746-52. PubMed ID: 20573757
[TBL] [Abstract][Full Text] [Related]
12. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
Connor KM; Shapiro RE; Diener HC; Lucas S; Kost J; Fan X; Fei K; Assaid C; Lines C; Ho TW
Neurology; 2009 Sep; 73(12):970-7. PubMed ID: 19770473
[TBL] [Abstract][Full Text] [Related]
13. Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead.
Ibrahimi K; Vermeersch S; Danser A; Villalón CM; van den Meiracker AH; de Hoon J; MaassenVanDenBrink A
Cephalalgia; 2014 Jun; 34(7):514-22. PubMed ID: 24391116
[TBL] [Abstract][Full Text] [Related]
14. Differential localization and characterization of functional calcitonin gene-related peptide receptors in human subcutaneous arteries.
Edvinsson L; Ahnstedt H; Larsen R; Sheykhzade M
Acta Physiol (Oxf); 2014 Apr; 210(4):811-22. PubMed ID: 24330354
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay.
Hershey JC; Corcoran HA; Baskin EP; Salvatore CA; Mosser S; Williams TM; Koblan KS; Hargreaves RJ; Kane SA
Regul Pept; 2005 Apr; 127(1-3):71-7. PubMed ID: 15680472
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model.
Vanmolkot FH; Van der Schueren BJ; de Hoon JN
Clin Pharmacol Ther; 2006 Mar; 79(3):263-73. PubMed ID: 16513450
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.
Salvatore CA; Moore EL; Calamari A; Cook JJ; Michener MS; O'Malley S; Miller PJ; Sur C; Williams DL; Zeng Z; Danziger A; Lynch JJ; Regan CP; Fay JF; Tang YS; Li CC; Pudvah NT; White RB; Bell IM; Gallicchio SN; Graham SL; Selnick HG; Vacca JP; Kane SA
J Pharmacol Exp Ther; 2010 Apr; 333(1):152-60. PubMed ID: 20065019
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.
Durham PL; Vause CV
CNS Drugs; 2010 Jul; 24(7):539-48. PubMed ID: 20433208
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.
Lynch JJ; Regan CP; Edvinsson L; Hargreaves RJ; Kane SA
J Cardiovasc Pharmacol; 2010 May; 55(5):518-21. PubMed ID: 20164785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
